2026-09-28T11:55:21.000Z · 1 day ago CervoMed announces PK results with new neflamapimod oral tablet formula
Sep 28, 2026, 7:30 AM EDT · 1 day ago CervoMed Announces Pharmacokinetic Results with New Neflamapimod Oral Tablet Formulation and Secures FDA Removal of Drug Exposure Limit
Sep 22, 2026, 7:30 AM EDT · 7 days ago CervoMed to Participate in the 5th Annual ROTH Healthcare Opportunities Conference
Sep 10, 2026, 7:30 AM EDT · 19 days ago CervoMed Announces Initial Results from the Phase 2a Clinical Trial of Neflamapimod in Nonfluent Variant Primary Progressive Aphasia (nfvPPA) Have Been Accepted as a Late-Breaking Oral Session at ISFTD 2026
Aug 10, 2026, 7:30 AM EDT · 7 weeks ago CervoMed Reports Second Quarter 2026 Financial Results and Provides Corporate Updates
Aug 5, 2026, 7:30 AM EDT · 7 weeks ago CervoMed to Participate in Fireside Chat to Highlight Recent Progress in the Neflamapimod Clinical Development Program at the Canaccord Genuity 46th Annual Growth Conference
Aug 4, 2026, 5:15 AM EDT · 1 month ago CervoMed Announces Neflamapimod Awarded Innovation Passport Designation Under the UK Innovative Licensing and Access Pathway (ILAP) for Treatment of Dementia with Lewy Bodies (DLB)
Jul 14, 2026, 7:30 AM EDT · 2 months ago CervoMed Announces New Clinical, Plasma Biomarker and Imaging Data at AAIC 2026 for Neflamapimod in the Treatment of Dementia with Lewy Bodies (DLB)
Jul 9, 2026, 7:30 AM EDT · 2 months ago CervoMed Announces Completion of Enrollment in Phase 2 Study of Neflamapimod for Nonfluent Variant Primary Progressive Aphasia, a Type of Frontotemporal Dementia
2026-07-06T21:05:17.000Z · 2 months ago CervoMed registers to sell 10.08M shares of common stock for holders
Jul 6, 2026, 7:30 AM EDT · 2 months ago CervoMed Showcases Leadership in Advancing the Treatment and Care of Dementia with Lewy Bodies at the Alzheimer's Association International Conference (AAIC) 2026
Jun 22, 2026, 4:05 PM EDT · 3 months ago CervoMed Announces Closing of $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
2026-06-18T16:40:10.000Z · 3 months ago CervoMed announces $10M registered direct offering priced at-the-market
Jun 18, 2026, 12:35 PM EDT · 3 months ago CervoMed Announces $10 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules
2026-06-18T11:11:15.000Z · 3 months ago CervoMed receives notice of allowance from USPTO on neflamapimod
Jun 18, 2026, 7:00 AM EDT · 3 months ago CervoMed Secures New U.S. Patent Protecting Use of Neflamapimod in Pure Dementia with Lewy Body Patients into 2042
Jun 12, 2026, 7:30 AM EDT · 3 months ago CervoMed to Participate in the H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
Jun 10, 2026, 7:30 AM EDT · 3 months ago CervoMed Announces Private Placement Financing and Plan to Focus on Strategic Partnering to Advance Neflamapimod into Phase 3 for Dementia with Lewy Bodies
May 18, 2026, 7:30 AM EDT · 4 months ago CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates
Apr 22, 2026, 7:30 AM EDT · 5 months ago CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies
Apr 7, 2026, 7:30 AM EDT · 5 months ago CervoMed to Provide Neflamapimod Clinical Program Update and Participate in a Panel on Biomarkers at 2026 Lewy Body Dementia Association Annual Meeting
Mar 19, 2026, 7:30 AM EDT · 6 months ago CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod's Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer's Disease Co-Pathology
2026-03-17T23:00:26.000Z · 6 months ago CervoMed price target lowered to $11 from $19 at Roth Capital
Mar 17, 2026, 7:30 AM EDT · 6 months ago CervoMed Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Updates
2026-03-12T11:27:04.000Z · 6 months ago CervoMed announces presentations at AP/PD 2026 scientific conference
Mar 4, 2026, 7:30 AM EST · 6 months ago CervoMed Announces Selection of Formulation and Dosing Regimen for Planned Phase 3 Trial in Patients with Dementia with Lewy Bodies
Feb 17, 2026, 8:00 AM EST · 7 months ago CERo Therapeutics Announces Biotech Industry Veteran Eric Francois to Join its Board of Directors SCYX
Dec 4, 2025, 5:00 PM EST · 9 months ago CervoMed Announces Late-Breaking Data at the 18th CTAD Conference Demonstrating Neflamapimod Significantly Slows Clinical Progression in Dementia with Lewy Bodies
Dec 2, 2025, 7:00 AM EST · 10 months ago CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)
Nov 24, 2025, 7:00 AM EST · 10 months ago CervoMed to Share New Data on Neflamapimod as a Treatment for Dementia with Lewy Bodies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference
Oct 8, 2025, 7:00 AM EDT · 11 months ago CervoMed Announces New Data from Phase 2b Trial Demonstrating Neflamapimod's Potential as a Treatment for Dementia with Lewy Bodies
Oct 2, 2025, 8:00 AM EDT · 12 months ago CervoMed to Participate in the 4th Annual ROTH Healthcare Opportunities Conference
Sep 17, 2025, 7:30 AM EDT · 1 year ago CervoMed Highlights Neflamapimod's Potential Benefits in Session on Dementia with Lewy Bodies at the 150th Annual American Neurology Association Conference
Jul 28, 2025, 7:00 AM EDT · 1 year ago CervoMed Announces 32-Week Data from RewinD-LB Trial Extension Phase Showing Neflamapimod's Sustained Effect on Slowing Clinical Progression in Patients with Dementia with Lewy Bodies and Associated Reduction in a Key Plasma Biomarker of Neurodegeneration
Jul 8, 2025, 7:00 AM EDT · 1 year ago CervoMed Announces Late-Breaking Presentations at Alzheimer's Association® International Congress 2025
May 12, 2025, 8:00 AM EDT · 1 year ago CervoMed Reports First Quarter 2025 Financial Results and Provides Corporate Updates
Mar 25, 2025, 8:00 AM EDT · 1 year ago CervoMed Announces Oral Presentation at 19th International Conference on Alzheimer's and Parkinson's Diseases and Related Neurologic Disorders (AP/PD™)
Mar 10, 2025, 4:05 PM EDT · 1 year ago CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies
Jan 29, 2025, 8:00 AM EST · 1 year ago CervoMed to Present at the 8th International Lewy Body Dementia Conference
Dec 12, 2024, 7:00 AM EST · 1 year ago CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Dec 10, 2024, 10:10 AM EST · 1 year ago CervoMed's stock craters 77% after failed trial of treatment for rare brain disease
Dec 10, 2024, 7:00 AM EST · 1 year ago CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy Bodies
Nov 27, 2024, 7:00 AM EST · 1 year ago CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal Dementia
Nov 12, 2024, 7:00 AM EST · 1 year ago CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
Nov 8, 2024, 9:55 AM EST · 1 year ago CervoMed Awarded the Prix Galien USA 2024 Prize for Best Startup
Nov 4, 2024, 8:00 AM EST · 1 year ago CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)
Oct 29, 2024, 8:00 AM EDT · 1 year ago CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia Conference
Oct 2, 2024, 8:00 AM EDT · 1 year ago CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities Conference
Aug 22, 2024, 8:00 AM EDT · 2 years ago CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy Bodies
Jul 30, 2024, 8:00 AM EDT · 2 years ago CervoMed to Participate in The Canaccord Genuity 44th Annual Growth Conference
Jul 11, 2024, 8:51 AM EDT · 2 years ago CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024